Treatments targeting inotropy - A position paper of the Committees on Translational Research and Acute Heart Failure of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC)

• Published in: European heart journal 2019, Vol.40 (44), p.3626-3644
• Main Authors: Maack, Christoph, Eschenhagen, Thomas, Hamdani, Nazha, Heinzel, Frank R, Lyon, Alexander, Manstein, Dietmar, Metzger, Joseph, Papp, Zoltán, Tocchetti, Carlo G, Birhan Yilmaz, M, Anker, Stefan D, Balligand, Jean-Luc, Bauersachs, Johann, Brutsaert, Dirk, Carrier, Lucie, Chlopicki, Stefan, Cleland, John G, de Boer, Rudolf A, Dietl, Alexander, Fischmeister, Rodolphe, Harjola, Veli-Pekka, Heymans, Stephane, Hilfiker-Kleiner, Denise, Holzmeister, Johannes, de Keulenaer, Gilles, Limongelli, Giuseppe, Linke, Wolfgang A, Lund, Lars H, Masip, Josep, Metra, Marco, Mueller, Christian, Pieske, Burkert, Ponikowski, Piotr, Ristić, Arsen, Ruschitzka, Frank, Seferović, Petar M, Skouri, Hadi, Zimmermann, Wolfram H., Mebazaa, Alexandre
• Format: Article
• Language: English
• Subjects: Cardiology and cardiovascular system; Human health and pathology; Life Sciences; Special
• ISSN: 0195-668X; 1522-9645
• DOI: 10.1093/eurheartj/ehy600

Acute heart failure (HF) and in particular, cardiogenic shock are associated with high morbidity and mortality. A therapeutic dilemma is that the use of positive inotropic agents, such as catecholamines or phosphodiesterase-inhibitors, is associated with increased mortality. Newer drugs, such as levosimendan or omecamtiv mecarbil, target sarcomeres to improve systolic function putatively without elevating intracellular Ca 2+ . Although meta-analyses of smaller trials suggested that levosimendan is associated with a better outcome than dobutamine, larger comparative trials failed to confirm this observation. For omecamtiv mecarbil, Phase II clinical trials suggest a favourable haemodynamic profile in patients with acute and chronic HF, and a Phase III morbidity/mortality trial in patients with chronic HF has recently begun. Here, we review the pathophysiological basis of systolic dysfunction in patients with HF and the mechanisms through which different inotropic agents improve cardiac function. Since adenosine triphosphate and reactive oxygen species production in mitochondria are intimately linked to the processes of excitation–contraction coupling, we also discuss the impact of inotropic agents on mitochondrial bioenergetics and redox regulation. Therefore, this position paper should help identify novel targets for treatments that could not only safely improve systolic and diastolic function acutely, but potentially also myocardial structure and function over a longer-term.